CoChat

β-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas

Open access
Nsengimana, Jérémie, Laye, Jon, Filia, Anastasia, O’Shea, Sally, Muralidhar, Sathya, Poźniak, Joanna, Droop, Alastair, Chan, May, Walker, Christy, Parkinson, Louise, Gascoyne, Joanne, Mell, Tracey, Polso, Minttu, Jewell, Rosalyn, Randerson-Moor, Juliette, Cook, Graham P., Bishop, D. Timothy, Newton-Bishop, Julia · 2018 · Journal of Clinical Investigation
Cited by 96

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Immunotherapy prolongs survival in only a subset of melanoma patients, highlighting the need to better understand the driver tumor microenvironment. We conducted bioinformatic analyses of 703 transcriptomes to probe the immune landscape of primary cutaneous melanomas in a population-ascertained cohort. We identified and validated 6 immunologically distinct subgroups, with the largest having the lowest immune scores and the poorest survival. This poor-prognosis subgroup exhibited expression profiles consistent with β-catenin-mediated failure to recruit CD141+ DCs. A second subgroup displayed an equally bad prognosis when histopathological factors were adjusted for, while 4 others maintained comparable survival profiles. The 6 subgroups were replicated in The Cancer Genome Atlas (TCGA) melanomas, where β-catenin signaling was also associated with low immune scores predominantly related to hypomethylation. The survival benefit of high immune scores was strongest in patients with double-WT tumors for BRAF and NRAS, less strong in BRAF-V600 mutants, and absent in NRAS (codons 12, 13, 61) mutants. In summary, we report evidence for a β-catenin-mediated immune evasion in 42% of melanoma primaries overall and in 73% of those with the worst outcome. We further report evidence for an interaction between oncogenic mutations and host response to melanoma, suggesting that patient stratification will improve immunotherapeutic outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci95351

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 96

Metadata

Authors
Nsengimana, J., Laye, J., Filia, A., O’Shea, S., Muralidhar, S., Poźniak, J., Droop, A., Chan, M., Walker, C., Parkinson, L., Gascoyne, J., Mell, T., Polso, M., Jewell, R., Randerson-Moor, J., Cook, G. P., Bishop, D. T., & Newton-Bishop, J.
Venue
Journal of Clinical Investigation
Published
2018-04-16
Volume
128
Issue
5
Pages
2048-2063
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2792414950
Cited by
96
References
21
FWCI
3.96
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: β-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas. https://app.cochat.ai/papers/10.1172/jci95351
The paper
Nsengimana, J., Laye, J., Filia, A., O’Shea, S., Muralidhar, S., Poźniak, J., Droop, A., Chan, M., Walker, C., Parkinson, L., Gascoyne, J., Mell, T., Polso, M., Jewell, R., Randerson-Moor, J., Cook, G. P., Bishop, D. T., & Newton-Bishop, J. (2018). β-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas. Journal of Clinical Investigation. https://doi.org/10.1172/jci95351

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.